Displaying drugs 1026 - 1050 of 1286 in total
MB-07803
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
Matched Description: … MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. …
Mimopezil
Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.
Investigational
Matched Description: … Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment …
Fulacimstat
Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction).
Investigational
Matched Description: … trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor …
Sunvozertinib
Sunvozertinib is under investigation in clinical trial NCT03974022 (Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)).
Investigational
Matched Description: … Sunvozertinib is under investigation in clinical trial NCT03974022 (Assessing an Oral EGFR Inhibitor, …
Besifovir dipivoxil
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Investigational
Matched Description: … Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. …
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
Matched Description: … Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary …
Toloxatone
Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .
Experimental
Matched Description: … It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388]. …
Camostat
Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the...
Experimental
Matched Description: … Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. …
BBT-877
BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
Investigational
Matched Description: … BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such …
9,10-Deepithio-9,10-Didehydroacanthifolicin
A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)
Experimental
Matched Description: … A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. …
Canertinib
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Matched Description: … Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma …
Amedalin
Amedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.
Experimental
Matched Description: … Amedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. …
INCB-9471
INCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.
Investigational
Matched Description: … It is a potent, selective inhibitor of the HIV-1 virus. …
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been …
RVT-3101
RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known …
Refametinib
Investigational
AZD-8186
AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).
Investigational
Matched Description: … AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel …
Merimepodib
Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
Investigational
Matched Description: … Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. …
Alrizomadlin
Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.[A257281,A257286]
Investigational
Matched Description: … Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. …
Pracinostat
Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
Investigational
Matched Description: … Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors …
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Matched Description: … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). …
Rineterkib
Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Investigational
Matched Description: … Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 …
Talsupram
Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to citalopram.
Experimental
Matched Description: … Talsupram is a selective norepinephrine reuptake inhibitor (NRI). …
Metralindole
Metralindole, also known as Inkazan, is similar in structure and pharmacology to pirlindole. It functions as a reversible inhibitor of monoamine oxidase A. In Russia, this drug was investigated for potential antidepressant activity.
Experimental
Matched Description: … It functions as a reversible inhibitor of monoamine oxidase A. …
Amonafide
Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.
Investigational
Displaying drugs 1026 - 1050 of 1286 in total